BioSpace News Archive

Cerevance today announced plans to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.

Biophytis SA announced that it has filed for approval on the Food and Drug Administration portal to launch its SARA-31 program in the U.S., the first ever Phase 3 study in sarcopenia.

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that uses the body’s immune system to fight cancer, announced that in a recent Company podcast its CEO, Ryan Davies, and Pyxis Oncology President & CEO, Dr. Lara Sullivan, discussed her journey as a biotech entrepreneur and executive at Pfizer.

Spinogenix, Inc. announced that it is open to enrollment having received approval from Australia’s Human Research Ethics Committee on June 26th to start human clinical trials with its novel drug SPG302 for the treatment of Amyotrophic Lateral Sclerosis.

The Wyss Center, a leading non-profit research center dedicated to innovating and accelerating technologies and therapies for neurological and mental health disorders, is pleased to announce the appointment of Craig Cook, MD, MBA, to the leadership team as Head of Business Development and Licensing.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, reported preliminary financial and operational highlights for the second quarter ended June 30, 2023.

Hillstream BioPharma (Nasdaq: HILS) a biotechnology company developing innovative therapeutic candidates targeting drug resistant and devastating cancers that can make a difference in patients’ lives, today announced a strategic reprioritization of its pipeline and provided a corporate update.

Artelo Biosciences, Inc. today announced that Gregory D. Gorgas, President & Chief Executive Officer of Artelo Biosciences, will be participating in the Benzinga All Access event taking place on Tuesday, July 11, 2023.

Broncus Holding Corporation has completed the first case of registered clinical trials of its targeted lung denervation radiofrequency ablation system.

Route 92 Medical, Inc. announced the appointment of Chris Hartman to the role of Chief Commercial Officer.